Be Smart Before You Donate BSB4uD (Cancer) - Comparing Non-Profits before you donate (see chart)

Note: best viewed in Firefox browser

  BSB4uD               ( Be Smart Before You Donate )

^So……. Always questions concerning donations? 

                       When it comes to donations, how much do you really know? 

Who do you believe, and why ?

How do you decide ?

Do you even care where you donate – if you donate?

Time or money or…..

Speaking of Trust:

Who gains?

What’s the priority?

Who loses?

Who leads?

Little, or nothing....... to gain /to lose?

Top down?  Bottom up?

^{It’s…….U}p to you to ask the right questions.  Be smart, it’s your right to ask -  your right to know.
    

Here’s a start – add your own

walk through this start of information - what you need or should  know & think about  but most likely don’t

Here’s the question:           I donate because.....

Have a look at the charts below to compare  ovarian cancer 
.....click on 'read more'

full access: Clinical Trial Information As a Measure of Quality Cancer Care -- Journal of Oncology Practice

BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patients with double primaries of the breasts and/or ovaries

Expert Reviews full access: On the advent of MSI testing of all colorectal cancers and a substantial part of other Lynch syndrome-related neoplasms

Worldwide, more than 1 million people present with colorectal cancer (CRC) annually. Of these, 2–5% occur in the context of Lynch syndrome (LS), the most common hereditary CRC predisposing syndrome (formerly designated as hereditary nonpolyposis CRC [HNPCC]). LS is characterized by a high lifetime risk for the development of CRC (20–70%), endometrial cancer (15–70%) and other extracolonic cancers (<15%). These extracolonic malignancies include carcinomas of the small intestine, stomach, pancreas and biliary tract, ovarium, brain, upper urinary tract and skin. .......germline mutation in one of the MMR genes MLH1, MSH2, MSH6 or PMS2.

Owing to the MMR deficiency in LS tumors, a microsatellite instability (MSI) phenotype is present. MSI, however, is also found in approximately 10–13% of sporadic CRCs (in total, MSI is present in approximately 15% of all CRCs). In addition to MSI, most LS tumors lack expression in the tumor cell nuclei of one of the four MMR proteins, MLH1, MSH2, MSH6 or PMS2.

Early detection of LS is of great importance, particularly in presymptomatic mutation carriers, since colonoscopic surveillance has proven to reduce CRC morbidity and mortality by 65–70% [6] and prophylactic surgery may prevent endometrial and ovarium carcinoma effectively.

Different models and strategies have been developed to identify patients with LS. In 1990, the Amsterdam criteria I were developed to provide a basis for uniformity in collaborative studies to find the disease-causing gene. These criteria were designed to be highly specific at the expense of sensitivity. They were criticized because extra-colonic tumors were not taken into account, thereby excluding classical LS families....Therefore, the Amsterdam criteria II were established in 1999"

Hyperthermic intra-peritoneal chemotherapy using Oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II

CONCLUSION:
Using intra-peritoneal Oxaliplatin associated with hyperthermia as consolidation therapy for advanced ovarian cancer results in a high risk of grade 3 morbidities with only a small benefit on survival